(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules...
Stats | |
---|---|
今日成交量 | 13 758.00 |
平均成交量 | 137 349 |
市值 | 141.47M |
EPS | $0 ( 2024-03-01 ) |
下一个收益日期 | ( $-0.150 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.930 |
ATR14 | $0.00500 (0.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Vazquez Chris | Buy | 22 | Series A Non-Voting Convertible Preferred Stock |
2024-04-05 | Strobeck Matthew | Buy | 7 392 | Series A Non-Voting Convertible Preferred Stock |
2024-04-05 | Strobeck Matthew | Buy | 1 304 | Series A Non-Voting Convertible Preferred Stock |
2024-04-05 | Schuler Jack W | Buy | 2 174 | Series A Non-Voting Convertible Preferred Stock |
2024-04-05 | Pestano Gary Anthony | Buy | 22 | Series A Non-Voting Convertible Preferred Stock |
INSIDER POWER |
---|
88.87 |
Last 100 transactions |
Buy: 13 131 293 | Sell: 601 205 |
音量 相关性
Biodesix, Inc. 相关性 - 货币/商品
Biodesix, Inc. 财务报表
Annual | 2023 |
营收: | $49.09M |
毛利润: | $33.21M (67.66 %) |
EPS: | $-0.640 |
FY | 2023 |
营收: | $49.09M |
毛利润: | $33.21M (67.66 %) |
EPS: | $-0.640 |
FY | 2022 |
营收: | $38.21M |
毛利润: | $24.06M (62.96 %) |
EPS: | $-1.910 |
FY | 2021 |
营收: | $54.51M |
毛利润: | $54.51M (100.00 %) |
EPS: | $-1.580 |
Financial Reports:
No articles found.
Biodesix, Inc.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。